Equity Profile

IRON

Disc Medicine, Inc.

Health CareBiotechnology$3.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing therapies for blood disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.74

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing therapies for blood disorders. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as the demand for innovative medical solutions grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q1-2026, Disc Medicine reported an EPS of $-1.65, which was a larger loss than analysts expected. The stock saw a slight decline of 0.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another significant loss this quarter, with an EPS consensus of $-1.74. The lack of revenue guidance adds uncertainty to investor expectations.

Bull Case

If the company can show progress in its pipeline or provide positive updates on upcoming therapies, it could lead to a more favorable outlook.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's financial stability and future prospects.

Key Metrics to Watch

EPS

$-1.74

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can management report on their drug development pipeline?

Updates on drug development are crucial for investor confidence and could influence future revenue potential.

Will there be any guidance on expected revenue streams in the coming quarters?

Any indication of future revenue could significantly impact market perception and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about the company's prospects, as they are not accounting for potential positive developments in the drug pipeline.

Supporting Evidence

The options market is pricing in a significant move, indicating that investors expect volatility and potential surprises.

Historical performance shows that the stock has reacted positively to unexpected advancements in drug development.

Key Risk

If management provides positive updates on their drug pipeline, it could shift investor sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be closely watched as investors seek clarity on the company's financial trajectory amid ongoing losses.

Bull Confirmed If

A smaller EPS loss than the consensus estimate of $-1.74 could indicate improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $-2.14 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations with a smaller loss, history suggests the stock could rise by around 0.64% on average.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A larger-than-expected loss could lead to a decline of approximately 0.64% based on historical patterns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug development pipeline and any upcoming clinical trials.
2Management's commentary on financial strategy and cost management.
3Any insights into potential partnerships or collaborations.
4Guidance on expected timelines for revenue generation.
5Responses to analyst questions regarding operational challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing therapies for blood disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.74

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q1-2026, Disc Medicine reported an EPS of $-1.65, which was a larger loss than analysts expected. The stock saw a slight decline of 0.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another significant loss this quarter, with an EPS consensus of $-1.74. The lack of revenue guidance adds uncertainty to investor expectations.

Bull Case

If the company can show progress in its pipeline or provide positive updates on upcoming therapies, it could lead to a more favorable outlook.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's financial stability and future prospects.

Key Metrics to Watch

EPS

$-1.74

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can management report on their drug development pipeline?

Updates on drug development are crucial for investor confidence and could influence future revenue potential.

Will there be any guidance on expected revenue streams in the coming quarters?

Any indication of future revenue could significantly impact market perception and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about the company's prospects, as they are not accounting for potential positive developments in the drug pipeline.

Supporting Evidence

The options market is pricing in a significant move, indicating that investors expect volatility and potential surprises.

Historical performance shows that the stock has reacted positively to unexpected advancements in drug development.

Key Risk

If management provides positive updates on their drug pipeline, it could shift investor sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be closely watched as investors seek clarity on the company's financial trajectory amid ongoing losses.

Bull Confirmed If

A smaller EPS loss than the consensus estimate of $-1.74 could indicate improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $-2.14 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations with a smaller loss, history suggests the stock could rise by around 0.64% on average.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A larger-than-expected loss could lead to a decline of approximately 0.64% based on historical patterns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug development pipeline and any upcoming clinical trials.
2Management's commentary on financial strategy and cost management.
3Any insights into potential partnerships or collaborations.
4Guidance on expected timelines for revenue generation.
5Responses to analyst questions regarding operational challenges.